Publication: Evaluación del tratamiento y de los modelos de clasificación del cáncer de células renales avanzado
Loading...
Files
Official URL
Full text at PDC
Publication Date
2018-02-19
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citations
Exportar
Abstract
El carcinoma de células renales (CCR) representa el 2-3% de todos los tumores, presenta una mayor incidencia en los hombres respecto a las mujeres en una proporción de 2:1 y entre los 60-70 años. El presente estudio realizado en el Hospital Universitario Central de Asturias (HUCA), hospital de referencia para el tratamiento del CCR dónde el cáncer de riñón tuvo una incidencia del 2.4% y un 2.5% de todas las muertes por cáncer ese mismo año. El CCR presenta una amplia variedad de factores pronósticos. Éstos se pueden clasificar en anatómicos, histológicos, clínicos y moleculares. En la actualidad, se usan los factores pronóstico clínicos para la clasificación de pacientes con CCR avanzado (CCRa). El modelo de clasificación utilizado en la mayoría de ensayos clínicos es el publicado en el Memorial Sloan-Kettering Cancer Center (MSKCC). Desde la publicación de la clasificación del MSKCC han ido apareciendo nuevos factores pronósticos ligados a la supervivencia del paciente así como nuevas formas de clasificación de los pacientes en función de éstos El tratamiento sistémico del CCRa también ha ido evolucionando, desde la irrupción en la práctica clínica de las citoquinas...
Renal cell carcinoma (RCC) represents 2-3% of all tumors with a higher incidence in men compared to women with a ratio of 2:1 aged between 60-70. The present study was conducted at the Central University Hospital of Asturias (HUCA) where kidney cancer had an incidence of 2.4% and accounted for 2.5% of all cancer deaths that year. The RCC has a wide variety of prognostic factors. These can be classified into anatomical, histological, molecular and clinical. Currently, clinical prognostic factors for the classification of patients with advanced RCC (RCCa) are used. The classification model used in most clinical trials is that published in the Memorial Sloan-Kettering Cancer Center (MSKCC). Since the publication of this classification, new prognostic factors related to patient survival and new ways of classifying patients according to these have appeared. RCC a systemic treatment has also evolved, since the eruption into clinical practice of cytokines...
Renal cell carcinoma (RCC) represents 2-3% of all tumors with a higher incidence in men compared to women with a ratio of 2:1 aged between 60-70. The present study was conducted at the Central University Hospital of Asturias (HUCA) where kidney cancer had an incidence of 2.4% and accounted for 2.5% of all cancer deaths that year. The RCC has a wide variety of prognostic factors. These can be classified into anatomical, histological, molecular and clinical. Currently, clinical prognostic factors for the classification of patients with advanced RCC (RCCa) are used. The classification model used in most clinical trials is that published in the Memorial Sloan-Kettering Cancer Center (MSKCC). Since the publication of this classification, new prognostic factors related to patient survival and new ways of classifying patients according to these have appeared. RCC a systemic treatment has also evolved, since the eruption into clinical practice of cytokines...
Description
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Farmacia, leída el 01-06-2017